Despite the advances in the management of ovarian cancer, the disease
remains the leading cause of death from gynecological malignancies. As
it generally remains confined to the peritoneal cavity, ovarian cance
r is an attractive target for radioimmunotherapy via the intraperitone
al route of administration. Several clinical trials have been carried
out investigating radiolabeled monoclonal antibodies and the results s
eem promising, especially in patients with small-volume residual disea
se after conventional therapy. Intraperitoneal radioimmunotherapy has
yet to prove itself as an important part of the treatment of ovarian c
ancer.